AstraZeneca said the two trials of elecoglipron met their primary endpoints.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 ...

AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates. As ...

AstraZeneca's revenue grew in the third quarter, boosted by the strength of the company's treatments pipeline. "We are...delivering on our strategy to strengthen our operations in the United States to ...

AstraZeneca (AZN.L, AZN.ST) is optimistic on earnings growth this year after logging a year-over-year increase in profit and ...

(Corrects to fix typo in paragraph 7) Feb 10 (Reuters) - AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer treatments and newer drugs as it pushes ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca PLC (AZN), RTX Corp. (RTX ...